These are stocks posting moves after the bell on Thursday, including: Insys Therapeutics, Lionsgate Entertainment, Time, Inc. and more.
The "Fast Money" traders share their final trades of the day, including General Motors, Bristol-Myers Squibb and more.
Doctors have found a disturbing downside to some powerful new drugs that harness the immune system to fight cancer, NBC News reports.
The "Fast Money" traders weigh the financial, technology, infrastructure and biotechnology sectors.
CNBC's Melissa Lee and the Options Action traders discuss the stocks they'll be watching next week.
Is health care so bad, it's good? With CNBC's Melissa Lee and the Options Action traders.
Google parent Alphabet just announced a $7 billion buyback this week, but buybacks overall have been declining this year.
U.S. equities closed lower on Thursday as investors parsed through a fresh batch of corporate earnings results and economic data.
Bristol-Myers Squibb CEO Giovanni Caforio told CNBC on Thursday he is confident in the company's pipeline and its portfolio.
CNBC's Meg Tirrell speaks to Bristol-Myers CEO Giovanni Caforio about his company's earnings and outlook, August drug trial results, the election and potential M&A.
Bristol-Myers Squibb raised its 2016 profit forecast after surprisingly strong quarterly sales for a handful of its other leading prescription drugs.
CNBC's Bob Pisani looks ahead at the day's market action.
U.S. stock futures pointed to a higher open as traders eyed a host of big earnings and the release of several pieces of data.
Some of the names on the move ahead of the open.
CNBC's Meg Tirrell reports on Bristol-Myers quarterly earnings.
Stocks could stay stalled in a range even if the next blast of earnings news is positive.
Jim Cramer goes through his lightning round of caller stocks, including what he sees ahead for Yum Brands after its split.
Jim Cramer broke down his thoughts on the current M&A market environment, and how regulators will react.
Now that earnings season is here, are third-quarter revenue estimates too high?
Third-quarter sales at the world's biggest maker of cancer drugs rose to $12.61 billion.